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Abstract: Clinical Genetics is concerned with the diagnosis and management of the medical, social and 
psychological aspects of hereditary disease. As in all other areas of medicine, it is essential to make the correct 
diagnosis and provide appropriate treatment which must include helping the affected person and family 
members llllderstand and come to terms with the nature and consequences of the disease. 
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INTRODUCTION 
When a disorder is susceptible of being heritable, 
there are other things that need to be taken in 
consideration; the need to inform other family members of 
the risk they have to contract the disease as well of the 
means available that help them to modify these risks. Just 
as the llllique feature of genetic disease is its tendency to 
recur within families, the mrique aspect of genetic 
cOllllselling is its focus, not only on the original patient, 
but also on the members of the patient's family, both 
present and future. Genetic COWlS elling, a core activity in 
medical genetics is concerned not only with informing the 
patient and the family but also with providing 
psychological oriented cOllllselling to help individuals 
adapt and adjust to the impact and implications of the 
disorder in the family (Nissbaurn e/ aI., 2004). The most 
common indications for genetic cOllllselling are: 
• Previous child with multiple congenital anomalies, 
mental retardation or an isolated birth defect such as 
neural tube defect, cleft lip and palate etc. 
• Family history of a heritable condition such as 
Fragile X syndrome, cystic fibrosis, thalessemia and 
Hlllltington disease 
• Consanguinity 
• As a follow up for a positive newborn test e.g after 
testing positive for PKU 
Established standards of medical care require that 
providers of genetic services obtain a history that 
includes family and etlmic information, advise patients as 
well as the other family member of the genetic risk, offer 
genetic testing or prenatal diagnosis when indicated and 
outline the various treatment or management options for 
reducing the risk of the disease (Andrews e/ aI., 1994). 
In some cases patients are not told what decisions to 
take as regards to the various testing and management 
options but instead are just provided with information 
and supportive care. This approach to cOllllselling also 
known as non directive cOllllselling has been adopted 
widely as the standard of practice in this field. 
CLINICAL APPLICATIONS OF CANCER GENETICS 
The ultimate goal of medical genetics is to improve 
the health and well being of the individuals, their families 
and society in general. With the information coming from 
the Hlllllan Genome project, it can anticipate that medical 
genetic technology, especially in the areas of testing and 
screening for hereditary disorders will have an even 
greater impact on the health and well being of the 
population. On the other hand, ethical values and social 
concerns must help shape the application of genetics so 
that we maximise the benefits and minimise any harm 
(Nissbaurn e/ aI., 2004). 
Genetic screening is used to identify persons with 
certain genotypes known to be associated with a genetic 
disease or a predisposition to a genetic disease. Genetic 
screening is an important public health activity that will 
become more significant as more and better screening 
tests become available for hereditary disease and for other 
conditions with an identifiable genetic component 
(Nissbaurn e/ aI., 2004). 
SCREENING OF NEWBORNS 
The best known public health efforts are the 
government programmes that carry out population 
screening of all newborns to identify genetic disorders 
like thalessemia and phenylketonuria, for which early 
treatment can prevent or at least ameliorate, the 
consequences. 
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The validity of the test results is particularly 
important, false positive results cause wmecessary 
concern to the parents, whereas false negative results 
vitiate the whole objective of the programme. 
Two heritable conditions clearly satisfy all these 
criteria, Phenylketonuria (PKU) and galactosaemia. The 
prototype of such disorder is PKU. Routine neonatal 
screening for PKU is mandatory by law in all but one of 
the states in the United States and in almost all developed 
cOlllltries. Galactosaemia screening is less common. A 
nwnber of other disorders such as sickle cell anaemia, 
congenital hearing loss, biotinidase deficiency, congenital 
adrenal hyperplasia ad various abnormalities of amino 
acid metabolism are less commonly screened for. The 
reasons for this are that they are not that common and 
effective treatment is not available (Andrews et al., 1994). 
Not everyone agrees that screening should be 
performed only for highly treatable conditions. It has been 
argued, for example that the newborn screening for cystic 
fibrosis or severe combined immllllodeficiency syndrome 
would benefit the newborn by allowing the institution of 
appropriate treatment while the newborn is relatively well, 
before the onset of malabsorption, failure to thrive and 
infections. For other conditions, such as Duchenne 
muscular dystrophy for which treatment is only palliative, 
early diagnosis might in theory, prompt genetic 
cOllllselling to help parents in their planning of future 
pregnancies (Chadwick. 1999). 
ADULT SCREENING 
The concept of newborn screening has been 
extended to include adult screening. One of the first 
disease that was screened for was haemochromatosis. 
This is a relatively common autosomal recessive disorder, 
in which there is an overload of iron. This can lead to 
permanent liver, pancreatic and cardiac damage. Screening 
could be performed either by direct detection of the 
muatant alleles or by measuring a biochemical parameter, 
such as transferrin levels depending on which test proves 
to be the most cost effective. Treatment by repeated 
venesection to remove the red blood cells or rather the 
iron they contain is highly effective in preventing organ 
damage if initiated before symptoms develop. Thus, 
population screening could identify asymptomatic 
homozygotes, early enough to prevent serious morbidity 
and mortality (Chadwick. 1999). 
HETEROZYGOTE SCREENING 
In contrast to screening for genetic disease m 
newborns and adults, screening for carriers has as its 
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mam purpose, the identification of individuals who are 
themselves healthy but are at risk of having children with 
a severe autosomal receSSIve or X linked illness 
(Harper. 1997). 
ClllTent heterozygous screening programmes have 
focused on particular etlmic groups in which the 
frequency of a disorder is high enough to justify 
screening. Heterozygote screening has so far been used 
routinely for Tay Sachs disease and Canavan disease, 
both in the Ashkenzaic Jewish population, sickle cell 
anaemia in the African American population of North 
America and ~-thalessemia in high incidence areas 
especially in Cyprus and Sardinia. Heterozygote screening 
is vollllltary and focuses on individuals who identify 
themselves as being members of a particular high risk 
ethnic group (Hudson et 01 .• 1995). 
The impact of carrier screening in lowering the 
incidence of a genetic disease can be dramatic. Screening 
the Ashkenzaic Jewish population for Tay-Sachs, 
followed by prenatal diagnosis has lowered the incidence 
ofTay Sachs by 65-85% in this ethic group. Prevention of 
~ thalessemia by carrier detection and prenatal diagnosis 
has brought about a similar drop in the incidence of 
disease in Cyprus and Sardinia. In contrast, attempts to 
screen for carriers of sickle cell anaemia in the US African 
American commllllity have been less effective and have 
had little effect so far (Hudson et 01.. 1995). 
ETIDCAL ISSUES IN MEDICAL GENETICS 
The successes of medical genetics have been 
accompanied by a parallel increase in ethical dilemmas 
and controversies. The new knowledge on screening and 
diagnosis of genetic disorders is to be used judiciously 
for the benefit and not to the detriment, of individuals, 
their families and society as a whole. With the initiation 
of the Hlllllan Genome project in the llllited states, the 
U. S. Congress recognised the ethical dilemmas and the 
potential for serious societal harm from the misuse of this 
vastly expanded knowledge of hlllllan genetics. The 
congress responded by mandating that a portion of the 
U. S. Hlllllan Genome Project budget is to be used to 
support Ethical. Legal and Social Implications (ELSI) of 
the project (Hudson et 01 .• 1995). 
In any discussion on ethical issues in medicine, three 
cardinal principles are frequently cited: beneficence 
(doing good for the patient) respect for individual 
autonomy (safeguarding an individual's rights to control 
his or he medical care and be free of coercion) and justice 
(ensuring that all individuals are treated equally and 
fairly). Complex ethical issues arise when these three 
cardinal principles are perceived to be in conflict with one 
another (Lapham et 01 .• 1996). 
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ETIDCAL DILEMMAS IN PRENATAL 
GENETIC TESTING 
Geneticists are frequently asked to help couples use 
prenatal diagnosis or assisted reproductive technology to 
avoid having offspring with a serious hereditary disorder. 
It should be recognised that for some hereditary 
disorders, prenatal diagnosis remains controversial, 
especially when the diagnosis leads to a decision to abort 
the pregnancy for a disease that is lllltreatable. The 
dilemma is even more acute when a couple makes a similar 
request for pregnancy that is not at risk for a serious 
disease or disability. The motivation for seeking prenatal 
diagnosis might include avoiding reClllTence of a disorder 
associated with a mild or a cosmetic defect or for selection 
of sex. The issue of sex selection for reasons other than 
reducing the risk for sex limited or X linked disease is a 
very contentious one. 
In the future particular alleles and genes that 
contribute to complex traits such as intelligence, 
personality, stature and other physical characteristics 
may possibly be identified during the course of the 
hwnan genome project. Will such non medical criteria be 
viewed as a justifiable basis for prenatal diagnosis? some 
might argue that parents are to varying extents, already 
expending tremendous effort and resources on 
improving the environmental factors that contribute to 
healthy successful children. They might therefore ask 
why not improve the genetic factors as well? Others 
consider prenatal selection for particular desirable genes 
as a dehwnanizing step that treats children simply as 
commodities fashioned for their parents' benefit 
(Lapham et 01.. 1996). 
Does the health professional have on the one hand 
a responsibility and on the other hand, the right to 
decide for a couple when a disorder is not serious 
enough to warrant prenatal diagnosis and abortion or 
assisted reproduction? The debate continues about where 
or even whether one can draw the line in deciding what 
constitutes a serious enough trait to warrant the 
application of premtal testing technology (Lapham et 01 .• 
1996). 
Another area of medical genetics in which ethical 
dilemmas frequently arise involves genetic testing that 
may have a much later onset in life than when the 
molecular testing is being performed. A good example of 
this is the testing done for HlIDtington disease. In this 
disease individuals CarryIng a mutant allele are 
asymptomatic early on in life but they will develop a 
devastating illness later on in life for which there is little 
or no treatment (Lapham et 01.. 1996). For any 
presymptomatic individual is knowledge of the test result 
22 
more beneficial thanhannful, or vice versa? How does the 
balance shift when testing for predisposing mutations 
that predispose to disease but may not inevitably cause 
disease? For example in autosomal dominant hereditary 
breast cancer, individuals carrying mutations in the 
BRCA1 or BRCA2 have a 50-90% chance of developing 
breast or ovarian cancer. Identifying heterozygote carriers 
could have benefits, because individuals at risk could 
choose to lIDdergo more frequent surveillance or 
preventive surgery such as mastectomy and 
oophorectomy. These measures reduce but do not 
eliminate the increased risk of breast cancer. On being 
tested for a predisposing gene mutation, these individuals 
incur the risk of stigmatization in their social lives 
and discrimination III Insurance and employment 
(Hudson et 01.. 1995). 
The ethical decision to be tested or not is an absolute 
decision made in a vacuwn. The patient must take an 
informed decision using all available information 
concerning the risk for and severity of the disease, the 
effectiveness of preventive and therapeutic measures 
and the potential harm that could arise from testing 
(Hudson et 01.. 1995). 
GENETIC TESTING IN CmLDREN 
Additional ethical problems arise when genetic testing 
involves children. As with adults, testing healthy children 
for late onset disease is beneficial if interventions that 
decrease morbidity or increase longevity are available. 
Genetic testing in children also carries the risk of 
stigmatisation, psychological damage and insurance and 
employment discrimination. This needs to be taken into 
consideration prior to testing. Another ethical principle 
that needs to be considered is autonomy. Children's 
autonomy their ability to make decisions for themselves 
about their own genetic constitution must be balanced 
with the desire of parents to obtain such information. 
There are various reasons why parents may wish to have 
their children tested. Some might argue that even if there 
are no clear medical interventions, it's the parents duty to 
inform and prepare their children for the future possibility 
of developing a serious illness. The parents may also seek 
this information for their own family planning 0 to avoid 
what some parents consider the corrosive effects of 
keeping important information about their children from 
them (Hudson et 01.. 1995). The preponderance of 
opinion among bioethicists is that lIDless there is a clear 
benefit to the child, testifying for a late onset disease or 
a carrier state should only be done when the child is 
sufficiently mature enough to take informed decisions 
(Lapham et 01..1996). 
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PRIVACY OF GENETIC INFORMATION 
AND ITS MISUSE 
A third major ethical principle, along with beneficence 
and respect to autonomy is justice-the requirement that 
everyone would be able to benefit equally from progress 
in medical genetics. Is it fair to stigmatize people who 
without a fault of their O\Vll are fOlllld to carry a genetic 
predisposition to a disease? 
As regard employment should employers be able to 
obtain genetic information in making hiring decisions, if 
that information helps them choose healthy employees 
with low absenteeism? Some have argued that an 
employer who fllllds an employee health care plan should 
have an access to such information in making hiring 
decisions so that the employer can refuse to hire 
individuals at risk of developing a serious illness later in 
life that could bankrupt the employee health plan 
(Pokorsi. 1997). 
In the area of life insurance, insurers insist that they 
must have an access to all pertinent genetic information 
about an individual that the individual himself or herself 
has. Life insurance companies calculate their premiwns 
based on actuarial tables of age specific smvival averaged 
over the population. Premiwns will not cover losses if 
individuals with private knowledge that they are at a 
higher risk for disease, conceal this information and buy 
extra life insurance (Pokorsi, 1997). 
As can be seen from the above examples, medical 
genetics will have a profOlllld impact beyond the narrow 
confines of medical practice. Integrating this knowledge 
into sOlllld public policy will require the coordinated 
efforts of government, employers and the public 
(Pokorsi. 1997). 
CONCLUSION 
It should be emphasised that genetic cOWlSelling IS 
not limited to the provision of information and calculation 
of the risk of the disease but it's a commmrication 
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process. The ability to define and address the complex 
psychosocial issues associated with a genetic disorder is 
central to this practice. 
In the future as the knowledge base of medical 
genetics expands, the scope of genetic cOllllselling will 
increase proportionately. For physicians, the challenge Is 
to appreciate the importance of genetic counselling in 
medical practice, to understand its scientific basis and to 
be aware of the limitations of their knowledge. Sir William 
Osler wrote in a clinical context but could have been well 
discussing genetic risk, errors of judgement are bound to 
occur in the practice of an art that consists largely in 
balancing probabilities. 
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